SMC Safety Review Shows PH-762 is Safe and Highly Effective in Skin Cancer Study
Phio Pharmaceuticals just took a confident step forward in its fight against skin cancer. The company's independent Safety Monitoring Committee (SMC) has wrapped up its safety review of all 22 patients completing the Phase 1b trial of PH-762, its lead clinical candidate—a gene-silencing siRNA therapy targeting the PD-1 gene. The SMC found no dose-limiting toxicities or serious adverse events, even as drug concentrations were increased 20-fold across five dose cohorts. This sets a notably clean safety profile for PH-762.
Maximum Dose Delivers 85% Pathological Response with No Major Safety Concerns
What makes these findings stand out? At the highest tested dose in the final patient cohort, PH-762 yielded an impressive 85% pathological response rate (meaning tumor shrinkage or clearance), with 4 out of 6 responders achieving complete tumor clearance. Across all dose groups, the overall response in patients with cutaneous squamous cell carcinoma (cSCC) was 65%. Importantly, no patients experienced disease progression, and the variety of responses ranged from partial to complete—all without triggering any significant toxicity.
| Cohort | Patients (n) | Highest Dose Pathological Response Rate | Complete Response in Cohort | Serious Adverse Events |
|---|---|---|---|---|
| Final Dose Cohort | 7 | 85% | 4 / 6 | 0 |
| All Cohorts | 22 (20 cSCC) | 65% (cSCC) | 9 (cSCC) | 0 |
Strong Data Supports Next Steps: FDA Submission and CMC Progress
The positive results offer Phio strong momentum heading into its next regulatory steps. A formal FDA submission is targeted for Q2 2026, aiming to guide future clinical trial designs. Manufacturing and process development for the drug’s active pharmaceutical ingredient are on track, with supplies expected for pre-clinical primate studies by March 2026. Such development is critical for advancing PH-762 into larger human trials.
Why This Matters: Setting a New Bar in Skin Cancer Treatment Safety and Response
The lack of serious adverse events—even at high doses—coupled with strong efficacy signals, puts PHIO in an encouraging position. Most notably, no patient saw their condition worsen throughout the trial. The more robust response at higher doses offers a compelling case for continued study of PH-762, especially for patients with few non-surgical treatment options.
Key Takeaways: Investors and Clinicians Eye PHIO’s Next Moves
While final data analysis and regulatory feedback are still pending, these latest results hint at the potential for PH-762 to become a valuable new approach in the skin cancer treatment landscape. Anyone tracking innovative biotech breakthroughs—or seeking non-surgical options for skin cancer—may want to keep a close eye on this developing story as PHIO moves toward pivotal trials later in 2026.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI